When to intubate in GCS?

GCS ≤ 8 requires intubation for airway protection. The patient cannot protect their own airway at this level of consciousness. Motor score is the most prognostically important component.

What is the best initial fluid for sepsis resuscitation?

Lactated Ringer's (LR) is the preferred resuscitation fluid. The SMART trial (2018) showed balanced crystalloids reduced death, new renal failure, and persistent renal dysfunction compared to normal saline.

When to start vasopressors in septic shock?

Start norepinephrine (first-line vasopressor) if MAP remains < 65 mmHg after initial 30 mL/kg crystalloid resuscitation, or earlier if patient is profoundly hypotensive. Do not delay pressors to complete full fluid resuscitation.

Why can serum uric acid be normal during acute gout?

During acute inflammation, IL-6 increases renal urate excretion and redistributes urate from plasma to tissues. Up to 40% of acute gout flares have normal serum uric acid. Joint aspiration with polarized microscopy is needed for definitive diagnosis.

How do you distinguish lupus flare from infection in SLE?

Key clues: CRP is low/normal in flare but elevated in infection. Complement (C3/C4) drops in flare but is normal/elevated in infection. Procalcitonin is elevated in bacterial infection but normal in flare. Anti-dsDNA rises in flare, stable in infection.

What is the difference between DKA and HHS?

DKA features acidosis (pH 600), hyperosmolality (> 320), and minimal ketosis -typically in Type 2 DM. DKA requires insulin drip; HHS requires aggressive fluid resuscitation first.

When to give tPA in acute ischemic stroke?

IV alteplase (tPA) can be given within 4.5 hours of last known well time in eligible patients. CT head must rule out hemorrhage first. For large vessel occlusion, mechanical thrombectomy can be performed up to 24 hours with favorable imaging.

What antibiotics for community-acquired pneumonia?

Inpatient non-ICU: ceftriaxone + azithromycin. ICU: ceftriaxone + azithromycin (add vancomycin if MRSA risk). Outpatient healthy: amoxicillin. Outpatient with comorbidities: augmentin + azithromycin or respiratory fluoroquinolone. Duration: 5 days if clinically stable for 48 hours.

How to interpret iron studies?

Iron deficiency: low ferritin (< 30), high TIBC, low iron, low transferrin saturation (< 20%). Anemia of chronic disease: normal/high ferritin (acute phase reactant), low TIBC, low iron. A ferritin of 50-100 in an inflamed patient may still represent iron deficiency.

What is the correction rate for hyponatremia?

Correct sodium no more than 8 mEq/L in 24 hours to avoid osmotic demyelination syndrome (ODS). For symptomatic severe hyponatremia with seizures, give 3% hypertonic saline 100-150 mL bolus over 10-20 minutes. If overcorrected, use D5W + DDAVP rescue protocol.

When to start antibiotics in meningitis?

Within 30-60 minutes. Do NOT delay antibiotics for LP or CT. Draw blood cultures, start empiric antibiotics (vancomycin + ceftriaxone ± ampicillin if > 50 or immunocompromised), then perform LP when possible. Dexamethasone should be given before or with the first antibiotic dose.

DOACs vs warfarin in antiphospholipid syndrome?

DOACs are contraindicated in APS. The TRAPS trial (2018) showed rivaroxaban was inferior to warfarin with more thrombotic events in triple-positive APS patients. Warfarin with INR target 2-3 is the standard for APS, indefinitely.

How to manage scleroderma renal crisis?

ACE inhibitors (captopril) are life-saving -start immediately and titrate aggressively. Do NOT hold for rising creatinine. Steroids > 15 mg prednisone per day precipitate scleroderma renal crisis. ARBs are NOT a substitute -evidence is only for ACEi.

What are the 4 pillars of heart failure treatment?

Guideline-directed medical therapy (GDMT) for HFrEF: (1) ARNI or ACEi/ARB, (2) beta-blocker (carvedilol, metoprolol succinate, or bisoprolol), (3) MRA (spironolactone or eplerenone), (4) SGLT2 inhibitor (dapagliflozin or empagliflozin). All four should be initiated and titrated to target doses.

AECOPD -Acute COPD Exacerbation -RoundsRx

🔍 Overview

What changed in GOLD 2026 (acute-care relevant points): (1) Pulmonary rehab within 4 weeks post-exacerbation strongly emphasized, reduces 1-year mortality and rehospitalization, plan it before discharge. (2) Biologics for severe eosinophilic COPD (mepolizumab, benralizumab, dupilumab) if blood eos ≥ 300 + frequent exacerbations on triple therapy, refer to outpatient pulm at discharge. (3) ICS without LABA is not appropriate, if you're discharging on inhaled steroid, pair it with LABA. Full GOLD 2026 changes (chronic).

Definition

AECOPD is a sustained worsening of respiratory symptoms -increased dyspnea, cough frequency, and/or sputum production (volume, purulence) -beyond normal day-to-day variation, requiring a change in therapy. Anthonisen 1987

This is the most common cause of COPD-related morbidity and mortality. Frequent exacerbators (≥ 2 per year) have accelerated lung function decline and reduced survival. ICU mortality ranges from 10–30%.

Severity Classification: Mild (bronchodilators only) | Moderate (requires antibiotics ± steroids) | Severe (hospitalization) | Very Severe (ICU admission)

Pathophysiology -Why COPD Patients Crash

The core problem is dynamic hyperinflation:

Trigger (infection, irritant) → airway inflammation → mucus plugging + bronchospasm → prolonged expiratory time → incomplete exhalation → air trapping → progressive hyperinflation → flattened diaphragm → reduced inspiratory capacity → respiratory muscle fatigue → hypercapnic respiratory failure.

Air stacking creates intrinsic PEEP (auto-PEEP), forcing patients to breathe against their own trapped air. This is why you see tripod positioning, pursed-lip breathing, and accessory muscle recruitment -they're desperately trying to empty their lungs before the next breath.

The 6 P's -Common Triggers of AECOPD

Mnemonic: 6 P's -~80% of AECOPD exacerbations have an identifiable trigger. Think through each P systematically.

#	P	Details
1	Pneumonia / Pulmonary infection	Most common trigger. Viral ~50% (rhinovirus, influenza, RSV, parainfluenza). Bacterial ~30% (H. influenzae, S. pneumoniae, M. catarrhalis).
2	Pulmonary embolism	~12% prevalence across hospitalized AECOPD overall; ~16% in unexplained AECOPD (Aleva meta-analysis 2017). Often missed. Always consider if no clear infectious trigger, pleuritic pain, unexplained tachycardia, or hypoxia out of proportion.
3	Pneumothorax	Especially in emphysematous patients with bullae. CXR mandatory on all AECOPD admissions.
4	Pleural effusion	Can worsen dyspnea and restrict lung expansion. Rule out on CXR.
5	Poor compliance	Missed inhalers (LAMA/LABA/ICS non-adherence) -very common and modifiable. Always ask about medication use.
6	Pollution / environmental	PM2.5, ozone spikes, cold air, biomass fuel smoke, occupational dust. Leading cause of COPD in low-income countries (biomass > smoking). Both a cause of COPD development and a trigger for exacerbations.

Don't Miss PE: PE occurs in ~12% of AECOPD hospitalizations overall (~16% in unexplained AECOPD) per Aleva meta-analysis 2017. Consider CTPA if: no clear infectious trigger, pleuritic pain, unexplained tachycardia, or hypoxia out of proportion to exam findings.

Also consider: Heart failure exacerbation (can mimic or co-precipitate AECOPD -check BNP), temperature extremes, and aspiration.

Common Mistake: Non-selective beta-blockers (propranolol, carvedilol), sedatives/opioids, and ACE inhibitors can trigger or worsen AECOPD. Always review the med list -ACE-inhibitor cough is frequently misdiagnosed as an exacerbation.

Clinical Presentation

Cardinal symptoms (Anthonisen criteria):

Increased dyspnea -most sensitive symptom
Increased sputum volume
Increased sputum purulence -green/yellow suggests bacterial infection

Physical exam findings:

Accessory muscle use (sternocleidomastoid, scalenes), tripod positioning
Pursed-lip breathing (creates back-pressure to prevent airway collapse)
Prolonged expiratory phase, diffuse expiratory wheezing
Tachypnea (RR > 24), tachycardia, diaphoresis
Cyanosis, asterixis (CO₂ retention), altered mental status

ICU Admission Criteria

Severe dyspnea unresponsive to initial therapy (continued accessory muscle use, unable to speak in sentences)
Altered mental status -confusion, somnolence, or coma
Persistent hypoxemia: SpO₂ < 88% despite FiO₂ ≥ 0.4
Severe or worsening respiratory acidosis: pH < 7.25 or PaCO₂ > 70 mmHg
Acidosis not improving with NIV (recheck ABG at 1–2 hours)
Hemodynamic instability requiring vasopressors
NIV intolerance or failure

Key Point: A rising PaCO₂ with falling pH despite maximal therapy is an indication for intubation. Don't wait for respiratory arrest.

🧪 Workup & Diagnosis

Immediate Assessment

ABG -mandatory in moderate-severe AECOPD. Assess pH, PaCO₂, PaO₂. Do NOT rely on SpO₂ alone.
CXR -exclude pneumonia, pneumothorax, pulmonary edema, pleural effusion
ECG -P pulmonale, right heart strain, arrhythmias (AF common in COPD)
CBC -leukocytosis (infection), polycythaemia (chronic hypoxia)
BMP -metabolic alkalosis (chronic CO₂ retainer), hypokalaemia (β₂ agonists)
BNP / NT-proBNP -exclude heart failure as trigger or co-contributor
Troponin if cardiac involvement suspected

ABG Interpretation in AECOPD

Pattern	pH	PaCO₂	HCO₃	Interpretation
Acute hypercapnia	< 7.35	> 45	Normal / mildly ↑	Acute exacerbation -treat aggressively
Chronic compensated	7.35–7.45	> 45	↑↑ (≥ 30)	Stable CO₂ retainer -know their baseline
Acute-on-chronic	< 7.35	> 45 (above baseline)	↑↑	Most common pattern -compensated chronically + acute decompensation
pH < 7.25	< 7.25	> 60	↑	Severe -NIV now, low threshold for intubation

CO₂ Retainer Pearl: Chronic CO₂ retainers have high HCO₃ as compensation. A "normal" PaCO₂ of 45 mmHg may represent acute decompensation in someone whose baseline is 60 mmHg. Always compare to prior ABG or clinic notes.

Sputum & Microbiology

Sputum Gram stain + culture if purulent sputum and no recent culture data
Respiratory viral panel (if influenza season -guides oseltamivir)
Legionella urine antigen + Pneumococcal urine antigen if severe / ICU
Procalcitonin -helps distinguish bacterial vs viral trigger PRORATA 2010
Consider CTPA if PE not excluded (atypical presentation, no clear infectious trigger)

Spirometry -Don't Do It Acutely

Do NOT perform spirometry during an acute exacerbation. Results are unreliable, the maneuver is uncomfortable, and it can worsen respiratory distress. Review prior PFTs in the chart for baseline FEV₁ context.

For chronic COPD baseline classification (GOLD Stage 1-4 by FEV₁ % predicted, GOLD ABE groups by symptoms + exacerbation history, inhaler step-up, biologics for eosinophilic phenotype), see the COPD Chronic Management topic. The acute exacerbation workflow below focuses on managing THIS event -not setting outpatient maintenance therapy.

🚨 Management

Don't Confuse the Protocol with Acute Asthma

⚠️ Same drugs, different protocol. Treating an AECOPD patient like an asthmatic (q20 min × 3 albuterol + 100% O₂) induces hypercapnia and hypoxic-drive crash. The first three decisions diverge:

Decision	AECOPD	Acute asthma
Albuterol frequency	q1–4 h scheduled, no q20 min loading	q20 min × 3 in first hour, front-loaded
Continuous nebs	Rarely, intermittent works; chronic patients don't tolerate continuous	Yes for severe (10–15 mg/hr)
Ipratropium duration	Continued throughout admission (often DuoNeb q4–6 h)	First 3 nebs only (ceiling effect, Rodrigo 2005)
O₂ target	88–92% (controlled O₂, avoid hypercapnic respiratory failure) AVOID, 2010	93–95%
Steroids	Prednisone 40 mg × 5 d REDUCE, 2013	Prednisone 40–60 mg × 5 d
Antibiotics	YES if Anthonisen ≥ 2 of 3 (↑ dyspnea, sputum volume, sputum purulence)	Usually NO
NIV	First-line for hypercapnic exacerbation (strong evidence, > 80% avoid intubation)	Bridge only, low threshold to intubate
IV magnesium	Not standard, weak evidence	2 g IV for severe (3Mg)
Decompensation tempo	Days	Hours

What's the same: dose per neb (albuterol 2.5–5 mg, ipratropium 0.5 mg), DuoNeb formulation, steroid burst with no taper if ≤ 5 days, sit upright. Full asthma acute protocol →

Management Algorithm

Immediately -Controlled Oxygen

Target SpO₂ 88–92% -and equally important: do NOT exceed 92% in known or suspected CO₂ retainers. Austin 2010

Why the upper limit matters:

Haldane effect -Dominant mechanism (~70%). Oxygenated Hb offloads CO₂ into plasma → PaCO₂ rises independent of respiratory rate.
V/Q mismatch -High FiO₂ abolishes hypoxic pulmonary vasoconstriction → blood flows to poorly-ventilated units → worsened dead space.
Hypoxic drive suppression -Correcting hypoxia reduces peripheral chemoreceptor drive → hypoventilation (real but overemphasized).

Practical approach: Start 1–2L NC, titrate to SpO₂ 88–92%. Check ABG within 30–60 min. If PaCO₂ rising despite target SpO₂ → escalate to NIV, not more O₂.

Common Error: Placing COPD patient on 15L NRB → arrives with PaCO₂ 90, pH 7.15. SpO₂ 100% is not reassuring in COPD -it may be the problem.

Bronchodilators -First-Line Treatment

Short-acting β₂ agonist (SABA) + short-acting muscarinic antagonist (SAMA) via nebuliser.
Albuterol (Ventolin) 2.5–5 mg + ipratropium (Atrovent) 0.5 mg neb q1h × 1–2 if severe, then scheduled q4–6h (or DuoNeb [albuterol + ipratropium pre-mix] combination, same schedule). Do NOT use the asthma q20 min × 3 loading regimen, AECOPD doesn't need it and chronic patients tolerate intermittent dosing better.
Continue ipratropium throughout admission (unlike asthma where it's stopped after 3 doses).
MDI + spacer equally effective as nebuliser in mild-moderate exacerbations (and doesn't aerosolise virus). Turner, 1997
Continuous salbutamol nebuliser only if severe bronchospasm not responding to intermittent dosing (less commonly needed in COPD than asthma).

Systemic Corticosteroids

Prednisolone 40 mg PO daily × 5 days -reduces treatment failure and length of stay. REDUCE, 2013 showed 5 days non-inferior to 14 days.
Use IV methylprednisolone 60 mg daily if unable to take PO (nil by mouth, vomiting) -equivalent to prednisone 40 mg PO, same 5-day course, no taper. Do NOT use 125 mg q6h (asthma-style dosing, not GOLD-aligned for AECOPD; lower-dose corticosteroids < 80 mg prednisone-equivalent are non-inferior).
No taper needed for 5-day course. Taper only if > 3 weeks of steroids.

🔄 Updated Practice: Old teaching: 10-14 day steroid course for COPD exacerbation. REDUCE 2013 showed 5 days of prednisone 40mg is non-inferior to 14 days. Shorter course = less hyperglycemia, less immunosuppression, same outcomes. Also: old teaching was to check theophylline levels and use IV aminophylline -this is rarely done anymore due to narrow therapeutic index and better alternatives.

Antibiotics (if indicated)

Antibiotics reduce treatment failure in moderate-severe AECOPD with purulent sputum. Anthonisen 1987
Anthonisen Criteria (all 3 = definitely treat; 2/3 = probably treat; 1/3 = no benefit):
① Increased dyspnea ② Increased sputum volume ③ Increased sputum purulence

Empiric choice: Amoxicillin-clavulanate 875/125 mg PO BID OR doxycycline 100 mg BID × 5–7 days. Levofloxacin if Pseudomonas risk (structural lung disease, frequent hospitalisation, recent abx).

Non-Invasive Ventilation (NIV / BiPAP) -Before Intubation

Start NIV early in hypercapnic respiratory failure (pH < 7.35 + PaCO₂ > 45). Reduces intubation rates, ICU mortality, and length of stay. Brochard 1995; Plant 2000

Initial settings: IPAP 12–16 cmH₂O, EPAP 4–5 cmH₂O. Titrate IPAP for patient comfort + TV 6–8 mL/kg. Add supplemental O₂ to maintain SpO₂ 88–92%.

NIV Contraindications: Reduced consciousness, inability to protect airway, vomiting, facial trauma/burns, hemodynamic instability, copious secretions, pH < 7.15 with poor trajectory.

Intubation -When NIV Fails or Contraindicated

RSI with cautious ventilator settings to avoid auto-PEEP.
Initial vent: TV 6–8 mL/kg IBW, RR 10–12/min (lower than ARDS!), I:E 1:3 or 1:4, PEEP 5 cmH₂O.
Low RR = more time for exhalation = less air trapping.
If hemodynamic collapse after intubation → disconnect ETT → manual exhalation (auto-PEEP release).
Check plateau pressure + perform expiratory hold for intrinsic PEEP measurement.

NIV Success vs Failure

Parameter	Good Response (1–2h)	NIV Failure → Intubate
pH	Improving toward 7.35	pH < 7.25 or worsening
PaCO₂	Decreasing	Rising despite NIV
RR	Decreasing	Still > 30 after 1–2h
HR	Decreasing	Worsening tachycardia
Mentation	More alert, cooperative	Worsening confusion, agitation
Accessory muscles	Decreasing	Unchanged or increasing

Discharge Criteria & Optimisation

Able to use inhalers correctly
Needs bronchodilators no more frequent than q4h
On room air or at baseline O₂ requirement
Able to eat and sleep without significant dyspnea
Clinically and hemodynamically stable for 12–24h
Maintenance therapy optimized (LAMA + LABA ± ICS reviewed and prescribed)
Smoking cessation counselling
Pulmonary rehab referral
Follow-up within 1–4 weeks

Swipe for more examples

📋 Case 1, Standard AECOPD Management

Patient: 68M with severe COPD (FEV1 35%), presents with worsening dyspnea × 3 days, productive cough with purulent sputum, RR 28, SpO₂ 86% on RA.

Immediate: O₂ via nasal cannula → target SpO₂ 88–92% (NOT 100% -risk of CO₂ retention in COPD). Start BiPAP if not improving (IPAP 12, EPAP 5).

Bronchodilators: Albuterol (ProAir) 2.5mg + ipratropium (Atrovent) 0.5mg nebs q20min × 3, then q4h.

Steroids: Prednisone (Deltasone) 40mg PO daily × 5 days (REDUCE trial -5 days = 14 days in outcomes).

Antibiotics: Azithromycin (Zithromax) 500mg PO daily × 3 days (indicated because purulent sputum -meets ≥ 2 of 3 Anthonisen criteria: ↑ dyspnea, ↑ sputum volume, ↑ sputum purulence).

ABG: pH 7.31, PaCO₂ 58, PaO₂ 62 → acute-on-chronic respiratory acidosis. BiPAP initiated. Repeat ABG in 1–2h.

Key: If BiPAP fails (worsening acidosis, inability to protect airway, AMS) → intubate. But BiPAP prevents intubation in ~75% of COPD exacerbations.

📋 Case 2, AECOPD Requiring Intubation

Patient: 74F with very severe COPD (FEV1 22%), brought in by EMS obtunded. RR 8, SpO₂ 78%, GCS 8. ABG: pH 7.12, PaCO₂ 95, PaO₂ 48.

This patient is too sick for BiPAP. Altered mental status + inability to protect airway = intubate.

Intubation strategy:

Pre-oxygenate with BVM at low rate, avoid breath-stacking in COPD.
RSI: Ketamine 1.5 mg/kg (bronchodilator properties, maintains hemodynamics) + rocuronium 1.2 mg/kg.
Ventilator settings: Low RR (10–12), TV 6–8 mL/kg IBW, long expiratory time (I:E ratio 1:4 or 1:5) to prevent auto-PEEP/breath-stacking.
Watch for auto-PEEP: If hypotension post-intubation → disconnect from vent for 10 seconds (releases trapped air). Most common cause of post-intubation hypotension in COPD.

Ongoing: Nebs via vent circuit. IV steroids (methylprednisolone 60 mg IV daily = prednisone 40 mg PO equivalent; transition to PO when able, 5-day total course, no taper). Antibiotics. Daily SBT when improving.

Key lesson: COPD + intubation = low rate, long expiratory time, watch for auto-PEEP. Post-intubation hypotension → disconnect and let air out before reaching for pressors.

📋 Case 3, AECOPD vs Pneumonia vs PE Overlap

Patient: 70M with moderate COPD, presents with dyspnea × 2 days, low-grade fever 38.2°C, HR 108, SpO₂ 89%. Treated as AECOPD with steroids, nebs, azithromycin. Not improving at 48h.

Re-evaluation:

CXR: Right lower lobe infiltrate → pneumonia, not just AECOPD. Need broader antibiotics.
D-dimer: 1,850 (elevated). Given immobility + tachycardia out of proportion → CTPA ordered → subsegmental PE found.
Procalcitonin: 0.8 → supports bacterial infection. Confirms need for antibiotics.

Revised treatment:

Upgrade antibiotics: Ceftriaxone 1g IV daily + azithromycin 500mg IV daily (CAP coverage).
Anticoagulation for PE: Heparin drip → transition to apixaban once stable.
Continue: Steroids, bronchodilators, O₂ targeting 88–92%.

Key lesson: When AECOPD doesn't improve in 48h → think beyond COPD. Get a CXR (pneumonia?), consider PE (especially if tachycardia out of proportion), and check procalcitonin. COPD patients often have overlapping diagnoses.

📋 Case 4, AECOPD with Pneumothorax

Patient: 62M with emphysema, sudden onset of severe dyspnea and pleuritic chest pain. SpO₂ 82%. Absent breath sounds on the right. Trachea midline.

CXR: Large right-sided pneumothorax (~40%). No mediastinal shift (simple pneumothorax, not tension, yet).

Why this matters in COPD:

COPD patients have minimal pulmonary reserve, even a small PTX can be life-threatening.
Bullous emphysema predisposes to spontaneous pneumothorax.
BiPAP/CPAP is CONTRAINDICATED with pneumothorax, positive pressure worsens it → tension PTX.

Treatment:

Chest tube (28-32Fr), large PTX in symptomatic COPD patient requires drainage, not observation.
High-flow O₂ (if no CO₂ retention risk) accelerates pleural air reabsorption.
Do NOT start BiPAP until tube is in place and lung is re-expanded.
If recurrent → pleurodesis (chemical or surgical) or VATS referral.
Treat underlying AECOPD concurrently (steroids, nebs, antibiotics if indicated).

Key lesson: Sudden worsening in COPD + absent breath sounds = get a CXR NOW. Rule out pneumothorax before slapping on BiPAP, positive pressure + PTX = tension physiology = cardiac arrest.

📋 Case 5, Frequent Exacerbator: Discharge Planning

Patient: 66F with COPD, 4th hospitalization for AECOPD in the past year. Currently stable on room air, ready for discharge. This is a frequent exacerbator phenotype, high risk of readmission and mortality.

Before discharge, optimization checklist:

Inhaler technique: Watch the patient use their inhalers. Up to 90% use them incorrectly. Teach, re-teach, and verify.
Triple therapy: ICS/LABA/LAMA (e.g., Trelegy Ellipta), reduces exacerbations by ~25% vs dual therapy. Consider if eosinophils ≥ 300.
Azithromycin prophylaxis: 250mg daily or 500mg 3×/week, reduces exacerbation frequency by ~27%. Check ECG (QTc) and hearing before starting. Avoid in NTM risk patients.
Pulmonary rehab referral: Single most impactful intervention for reducing readmissions. Start within 4 weeks of discharge.
Smoking cessation: If still smoking, varenicline (Chantix) + counseling. Only intervention that changes disease trajectory.
Vaccinations: Influenza (annually), pneumococcal (PCV20), COVID, RSV (if ≥ 60).
Home O₂: If resting SpO₂ ≤ 88% or PaO₂ ≤ 55 on stable state, refer for home O₂ (improves mortality in hypoxemic COPD).
Action plan: Written instructions for when to start prednisone burst + antibiotics at home vs call vs go to ED.

Key lesson: The real COPD management happens at discharge, not during the admission. Optimize inhalers, start prophylactic azithromycin, refer to pulm rehab, and give a written action plan. This prevents the next admission.

💊 Medications & Doses

Bronchodilators

Drug	Class	Dose (Acute)	Notes
Albuterol (Ventolin, ProAir)	SABA	2.5–5 mg neb q1h × 1–2 if severe, then q4–6h scheduled. Continuous 10–15 mg/hr only for refractory bronchospasm.	First-line. Watch hypokalemia and β₂-driven lactic acidosis with frequent dosing. Do NOT use the asthma q20 min × 3 protocol.
Ipratropium (Atrovent)	SAMA	0.5 mg neb q4–6h, continued throughout admission	Combine with albuterol, additive bronchodilation. Less tachycardia. Unlike asthma, ipratropium has sustained benefit in COPD (don't stop after 3 doses).
Albuterol + Ipratropium (DuoNeb)	SABA+SAMA	2.5/0.5 mg neb q1h × 1–2 if severe, then q4–6h scheduled	Single-vial combination, preferred in acute setting for convenience. Same schedule as separate components.
Magnesium sulphate	Smooth muscle relaxant	1.2–2g IV over 20 min	Consider in severe/refractory bronchospasm -evidence mainly from asthma but used in COPD

Corticosteroids

Drug	Dose	Duration	Evidence
Prednisolone (Orapred)	40 mg PO daily	5 days REDUCE, 2013	Non-inferior to 14 days; reduces treatment failure and LOS
Methylprednisolone (Solu-Medrol)	60 mg IV daily (equivalent to prednisone 40 mg PO)	5 days, switch to PO when able. No taper.	Use only if nil by mouth / unable to absorb PO. Avoid 125 mg q6h -asthma-style dosing, not GOLD-aligned for AECOPD. Lower-dose corticosteroids (< 80 mg prednisone-equivalent) non-inferior to higher doses.
Dexamethasone (Decadron)	6 mg IV/PO daily (= prednisone 40 mg equivalent)	5 days, no taper	Alternative; longer half-life, once-daily dosing. Avoid 8 mg -that is ~53 mg prednisone-equivalent, exceeds the GOLD-recommended 40 mg-equivalent target.

Antibiotics

Drug	Dose	Indication	Notes
Amoxicillin-clavulanate	875/125 mg PO BID × 5–7d	First-line moderate AECOPD with purulent sputum	Covers H. influenzae, S. pneumo, M. catarrhalis
Doxycycline (Vibramycin)	100 mg PO BID × 5–7d	Alternative to amox-clav	Good atypical coverage; useful if penicillin allergy
Azithromycin (Zithromax)	500 mg PO × 1, then 250 mg daily × 4d	Atypical coverage, macrolide option	Resistance rates rising; QTc monitoring
Levofloxacin (Levaquin)	500–750 mg PO/IV daily × 5–7d	Pseudomonas risk, structural lung disease, frequent hospitalisations	QTc prolongation; Achilles tendon rupture risk; reserve for high-resistance risk
Piperacillin-tazobactam (Zosyn)	3.375g q6h IV	ICU-level AECOPD with Pseudomonas risk	Bronchiectasis, structural lung disease, prior Pseudomonas isolation

Procalcitonin-Guided Antibiotics: PCT < 0.1 = unlikely bacterial → withhold antibiotics. PCT 0.1–0.25 = equivocal. PCT > 0.25 = bacterial → treat. Reduces antibiotic prescription without affecting clinical outcomes. ProHOSP, 2009 (PRORATA 2010 was an ICU sepsis trial -separate evidence base, do not conflate.)

Maintenance Therapy -Initiate Before Discharge

Drug Class	Example	Notes
LAMA (Long-acting muscarinic antagonist)	Tiotropium (Spiriva) 18 mcg daily	Reduces exacerbation frequency. Most important maintenance drug. UPLIFT, 2008
LABA (Long-acting β₂ agonist)	Salmeterol or Formoterol	Add to LAMA in moderate-severe disease
ICS + LABA	Budesonide/Formoterol	Add ICS if ≥ 2 exacerbations/year or eosinophils ≥ 300. IMPACT, 2018 -triple therapy reduces exacerbations
Roflumilast	500 mcg PO daily	PDE4 inhibitor. Add in severe COPD (FEV₁ < 50%, chronic bronchitis, frequent exacerbations). GI side effects common.
Azithromycin prophylaxis	250 mg 3×/week or 500 mg daily	Reduces exacerbation frequency in former/non-smokers. Albert 2011. Monitor QTc + hearing.

📋 On Rounds

On Rounds

Pimp Questions

Why do we target SpO₂ 88–92% in COPD and not 94–98%?

Three mechanisms, ranked by contribution: (1) Haldane effect (dominant, ~70%) -deoxyHb binds CO₂ ~3.5× more efficiently than oxyHb. Fully saturating Hb with O₂ offloads CO₂ into plasma → PaCO₂ rises even without any change in breathing. (2) V/Q mismatch worsening -high FiO₂ abolishes hypoxic pulmonary vasoconstriction → blood floods poorly-ventilated alveoli → dead space increases → CO₂ retention

What is auto-PEEP and how does it affect management in intubated COPD?

Auto-PEEP (intrinsic PEEP) occurs when air trapping prevents complete exhalation before the next breath is delivered. Gas accumulates → lung hyperinflation → increased intrathoracic pressure → reduced venous return → hemodynamic compromise. Detected by expiratory hold maneuver. Managed by: low RR (10–12/min), prolonged I:E (1:3 to 1:4), low set PEEP (3–5 cmH₂O), bronchodilators, suctioning.

When do antibiotics help in AECOPD and when don't they?

The Anthonisen 1987 landmark trial defined 3 cardinal symptoms: increased dyspnea, increased sputum volume, and increased sputum purulence. Antibiotics benefit patients with all 3 symptoms (NNT ~3–4) or those requiring NIV/intubation. Only 1 symptom present = no antibiotic benefit. Procalcitonin can help guide the decision -PCT < 0.1 suggests viral etiology, withhold antibiotics. PRORATA 2010

NIV vs intubation -when do you escalate?

NIV reduces intubation, mortality, and LOS in hypercapnic AECOPD with pH 7.25–7.35 Brochard 1995. Reassess at 1–2h. Intubate if: pH < 7.25 or worsening, PaCO₂ rising on NIV, RR still > 30, worsening consciousness/agitation, inability to clear secretions, hemodynamic instability. Don't wait too long -a crashing COPD patient is technically difficult to intubate (hyperinflation → hemodynamic instability on intubation).

Clinical Examples

📋 Case 1, Severe AECOPD Requiring NIV

Patient: 68M with GOLD 3 COPD (FEV1 35%), current smoker, presents with 3 days of worsening dyspnea, increased purulent sputum, and confusion. Uses tiotropium and PRN albuterol at home.

Key findings: RR 28, SpO2 82% on RA, HR 110, accessory muscle use, tripod position. ABG on 2L NC: pH 7.28, PaCO2 78, PaO2 55. CXR: hyperinflation, no infiltrate. Procalcitonin 0.08.

Management:

Albuterol/ipratropium (DuoNeb) q20min x 3, then q4h. Target SpO2 88-92% Austin, 2010
BiPAP: IPAP 12-14 / EPAP 5, titrate to comfort. Reassess ABG in 1-2h
Prednisone 40 mg PO daily x 5 days (no taper needed) REDUCE, 2013
Antibiotics: amoxicillin-clavulanate (Anthonisen Type 1 -- all 3 cardinal symptoms present)

Teaching point: NIV is the most important intervention in hypercapnic AECOPD (pH 7.25-7.35). The Haldane effect -- not suppression of hypoxic drive -- is the main reason over-oxygenation worsens CO2 retention.

📋 Case 2, Intubated COPD with Auto-PEEP

Patient: 72F with severe COPD, intubated for respiratory failure after failing NIV (pH 7.18, obtunded). 20 minutes post-intubation, BP drops to 70/40, HR rising to 130.

Key findings: Vent settings: AC 16/500/FiO2 60%/PEEP 5. Peak airway pressure 45 cmH2O. Expiratory flow waveform does not return to zero (air trapping). Expiratory hold: intrinsic PEEP 14 cmH2O. Bilateral breath sounds present (not pneumothorax).

Management:

Immediate: disconnect ETT from vent for 30-60 seconds (passive exhalation). BP recovers = confirms auto-PEEP
Adjust vent: decrease RR to 10-12, prolong I:E to 1:4, reduce tidal volume, set extrinsic PEEP to ~80% of measured auto-PEEP
Aggressive bronchodilation: continuous albuterol via in-line nebulizer + IV magnesium 2g
Deep sedation + paralysis if severe air trapping persists (eliminate patient-ventilator dyssynchrony)

Teaching point: Hypotension after intubation in COPD = auto-PEEP until proven otherwise. Disconnecting from the vent is both diagnostic and therapeutic. Three causes of post-intubation hypotension: auto-PEEP, tension pneumothorax, and sedation-induced vasodilation.

📋 Case 3, Mild AECOPD with Discharge Planning

Patient: 58F with moderate COPD (GOLD 2, FEV1 55%), presents with 4 days of increased dyspnea and change in sputum color. No accessory muscle use. Uses albuterol PRN only -- not on any maintenance inhaler.

Key findings: RR 20, SpO2 93% on RA, HR 88. Diffuse expiratory wheezing. ABG: pH 7.38, PaCO2 42. CXR: hyperinflation only. Procalcitonin 0.35.

Management:

DuoNeb q4h, prednisone 40 mg PO daily x 5 days
Doxycycline 100 mg BID x 5 days (Anthonisen Type 2 -- dyspnea + purulence)
Observe 24h. If improving: discharge with prednisone, antibiotic, and albuterol MDI
Critical discharge intervention: Start LABA/ICS maintenance inhaler. Refer for pulmonary rehab. Smoking cessation counseling and NRT

Teaching point: Every AECOPD admission is an opportunity to optimize maintenance therapy and address smoking cessation. Pulmonary rehabilitation is the single most effective non-pharmacologic intervention for reducing future exacerbations.

📋 Sample Presentation

"Mr. Davies is a 67-year-old ex-smoker with GOLD 3 COPD who presented with 3 days of worsening dyspnea, increased purulent sputum, and confusion. On arrival he was in moderate respiratory distress -RR 28, SpO₂ 82% on room air, using accessory muscles. ABG showed pH 7.28, PaCO₂ 78, PaO₂ 52 on 2L NC. CXR showed hyperinflation with no new infiltrate. He was started on albuterol/ipratropium (DuoNeb) nebs, prednisolone 40 mg, and amoxicillin-clavulanate. NIV was initiated -IPAP 14 / EPAP 5 -with SpO₂ target 88–92%. Repeat ABG at 2 hours showed pH 7.34, PaCO₂ 68 -improving on NIV. He is now more alert, RR 20, on NIV cycling with breaks for meals. Today's plan: continue NIV, wean to Venturi mask for meals, antibiotic day 2, maintain O₂ target 88–92%."

Rounds Checklist

SpO₂ 88–92% confirmed? Not on high-flow O₂?
Latest ABG -pH and PaCO₂ trend?
NIV hours per day? Mask tolerance?
Bronchodilator frequency -still q4h? Ready to wean to q6h?
Steroid day #? (5-day course)
Antibiotic day #? (5–7 days). Sputum cultures back?
Potassium -check daily with frequent nebs
Glucose -steroid hyperglycaemia?
Ambulation -physio ordered?
Discharge planning -inhalers correct technique, follow-up, smoking cessation

Monitoring Protocol

Parameter	Frequency	Target / Action
SpO₂	Continuous	88–92% in CO₂ retainers. NOT 94–98%.
ABG	At 30–60 min after O₂/NIV start, then q4–6h if on NIV	pH improving, PaCO₂ stable or falling
RR, accessory muscle use	q1–2h	RR decreasing; less accessory muscle use = good response
Mental status	q1–2h on NIV	Worsening confusion → intubate
Potassium	q4–6h if frequent nebs	Hypokalaemia with frequent salbutamol + steroids; replace aggressively
Glucose	q6h if on steroids	Steroid hyperglycaemia -use insulin sliding scale
ECG	On admission + PRN	New AF common in AECOPD; rate control with diltiazem or digoxin (avoid BB)
CXR	On admission, repeat if worsening	Exclude new pneumonia, pneumothorax, effusion

NIV Monitoring Checklist

Check ABG 1–2h after starting NIV -if no improvement → escalate
Mask fit -leaks significantly reduce effectiveness
Patient tolerance -sedation is NOT used with NIV (risks aspiration)
Titrate IPAP for TV 6–8 mL/kg and patient comfort
SpO₂ 88–92% while on NIV
Reassess every 2–4h -early identification of NIV failure critical

Ventilator Settings if Intubated

Parameter	Setting	Rationale
Mode	AC/VC	Volume control preferred for predictable TV delivery
Tidal volume	6–8 mL/kg IBW	Lower than ARDS -compliance better but still protect lungs
Rate	10–12 /min (low!)	Low RR = more time to exhale = less auto-PEEP
I:E ratio	1:3 to 1:4	Prolonged expiratory time to reduce air trapping
PEEP	3–5 cmH₂O (low)	Counter auto-PEEP partially; high PEEP worsens hyperinflation
FiO₂	Titrate to SpO₂ 88–92%	Same target as non-intubated

Post-Intubation Hypotension: Severe auto-PEEP → impaired venous return → hemodynamic collapse. Disconnect ETT, allow passive exhalation. Give IV fluid bolus. Reduce RR.

⚡ Summary

Summary

O₂ Target

88–92% in known/suspected CO₂ retainers. NOT high-flow. Titrate O₂ and check ABG in 30–60 min.

Bronchodilators

Albuterol (Ventolin) + ipratropium (Atrovent) neb q20 min × 3 → q4–6h, or DuoNeb. MDI + spacer equally effective in mild-moderate cases.

Steroids

Prednisolone 40 mg PO × 5 days. Equal to 14 days. IV methylprednisolone if nil by mouth. REDUCE, 2013

Antibiotics

Give if 2–3 Anthonisen criteria present (dyspnea ↑ + sputum ↑ + purulence). Amox-clav or doxycycline × 5–7d. Fluoro if Pseudomonas risk.

NIV

Start early for pH < 7.35 + PaCO₂ > 45. Reduces intubation + mortality. Brochard 1995. Check ABG at 1–2h. Failure → intubate.

Intubation Settings

Low RR (10–12), I:E 1:3 to 1:4, low PEEP (3–5). High auto-PEEP → disconnect ETT + manual exhalation if hemodynamic collapse.

Don't Miss

PE in AECOPD (up to 25%). No infectious trigger → consider CTPA. Also AF (rate control) and HF co-exacerbation.

Before Discharge

Optimise inhalers (LAMA ± LABA ± ICS). Smoking cessation. Pulmonary rehab referral. Follow-up in 1–4 weeks.

📄 One Pager

Pulmonology · ICU · One Pager

AECOPD

Target O₂ 88–92%, NOT 94–98%. NIV before intubation. 5-day steroids. Antibiotics only if 2–3 Anthonisen criteria. Don't miss PE.

💨 Anthonisen Criteria

① Increased dyspnea
② Increased sputum volume
③ Increased sputum purulence

2–3 present → give antibiotics Anthonisen 1987
1 present → no antibiotic benefit

🩸 ABG -Severity Guide

pH 7.35–7.45 + ↑PaCO₂Chronic compensated

pH < 7.35 + ↑PaCO₂Acute -start NIV

pH < 7.25Severe -low threshold intubate

pH < 7.15Intubate -NIV failing

🚨 Management -Step by Step

1

O₂ target 88–92% -start 1–2L NC, titrate up. Check ABG at 30–60 min. Austin 2010

2

Bronchodilators: Albuterol (Ventolin) 2.5–5 mg + ipratropium (Atrovent) 0.5 mg neb q20 min × 3 → q4–6h, or DuoNeb

3

Steroids: Prednisolone 40 mg PO × 5 days REDUCE, 2013

4

Antibiotics if ≥ 2 Anthonisen criteria: Amox-clav 875/125 mg BID or doxycycline × 5–7d

5

NIV (BiPAP) if pH < 7.35 + PaCO₂ > 45 -IPAP 12–16, EPAP 4–5. Check ABG at 1–2h. Brochard 1995

6

Intubate if NIV fails (pH worsening, AMS, RR still > 30). Low RR (10–12), I:E 1:3, low PEEP.

💊 Key Drugs

Albuterol (Ventolin)2.5–5 mg neb q20 min

Ipratropium0.5 mg neb q20 min

Prednisolone40 mg PO × 5d

Amox-clav875/125 mg PO BID × 5–7d

📊 Monitoring

SpO₂ 88–92% target
ABG at 1–2h after NIV start
K⁺ daily (salbutamol + steroids)
Glucose q6h (steroids)
ECG -new AF common

⚠️ Pitfalls

High-flow O₂ → CO₂ retention
Steroids > 5 days (not needed)
Antibiotics for viral AECOPD
Missing PE as trigger
High PEEP in auto-PEEP patient
High RR on vent → air trapping

✅ NIV Success Criteria (check at 1–2h)

pH improving toward 7.35
PaCO₂ stable or falling
RR decreasing
More alert and cooperative
Accessory muscle use decreasing

🎓 Key Trials

Brochard 1995: NIV reduces intubation + mortality
REDUCE 2013: 5d steroids = 14d
Anthonisen 1987: Antibiotic criteria
Austin 2010: Titrated O₂ reduces mortality 58%
UPLIFT 2008: Tiotropium reduces exacerbations

Acute Exacerbation of COPD (AECOPD)